Policy Statement Adults
The use of the automatic implantable cardioverter defibrillator (ICD) may be considered medically necessary in adults who meet any of the following criteria:
Primary Prevention
• Ischemic cardiomyopathy and all of the following: o Judged to be at high risk for sudden cardiac death by a physician experienced in the care of patients with HCM o One or more of the following major risk factors for sudden cardiac death:
 History of premature HCM-related sudden death in one or more first-degree relatives younger than 50 years  Left ventricular hypertrophy greater than 30 mm  One or more runs of nonsustained ventricular tachycardia at heart rates of 120 beats per minute or greater on 24-hour Holter monitoring  Prior unexplained syncope inconsistent with neurocardiogenic origin • Diagnosis of any one of the following cardiac ion channelopathies and considered to be at high risk for sudden cardiac death (see Policy Guidelines section): o Congenital long QT syndrome o Brugada syndrome o Short QT syndrome o Catecholaminergic polymorphic ventricular tachycardia
Secondary Prevention
• Patients with a history of a life-threatening clinical event associated with ventricular arrhythmic events such as sustained ventricular tachyarrhythmia, after reversible causes (e.g., acute ischemia) have been excluded
The use of the ICD is considered investigational in primary prevention patients who have had any of the following risk factors:
• History of an acute myocardial infarction (i.e., less than 40 days before ICD treatment)
• New York Heart Association (NYHA) class IV congestive heart failure (unless patient is eligible to receive a combination cardiac resynchronization therapy ICD device) • History of a cardiac revascularization procedure in past 3 months (coronary artery bypass graft [CABG] or percutaneous transluminal coronary angioplasty [PTCA]) • Candidates for a cardiac revascularization procedure • Have noncardiac disease that would be associated with life expectancy less than 1 year
The use of the ICD for secondary prevention is considered investigational for patients who do not meet the criteria for secondary prevention.
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Pediatrics
The use of the ICD may be considered medically necessary in children who meet any of the following criteria:
• Survivors of cardiac arrest, after reversible causes have been excluded • Symptomatic, sustained ventricular tachycardia in association with congenital heart disease in patients who have undergone hemodynamic and electrophysiologic evaluation • Congenital heart disease with recurrent syncope of undetermined origin in the presence of ventricular dysfunction or inducible ventricular arrhythmias • Hypertrophic cardiomyopathy (HCM) with both of the following:
o Judged to be at high risk for sudden cardiac death by a physician experienced in the care of patients with HCM o One or more of the following major risk factors for sudden cardiac death:
 History of premature HCM-related sudden death in one or more first-degree relatives younger than 50 years of age  Massive left ventricular hypertrophy based on age-specific norms  Prior unexplained syncope inconsistent with neurocardiogenic origin • Diagnosis of any one of the following cardiac ion channelopathies and considered to be at high risk for sudden cardiac death (see policy guidelines): o Congenital long QT syndrome o Brugada syndrome o Short QT syndrome o Catecholaminergic polymorphic ventricular tachycardia
The use of the ICD is considered investigational for all other indications in pediatric patients.
Subcutaneous ICD
The use of a subcutaneous ICD may be considered medically necessary for adults or children who have an indication for ICD implantation for primary or secondary prevention for any of the above reasons and meet all of the following criteria:
• Have a contraindication to a transvenous ICD due to one or more of the following: o Lack of adequate vascular access o Compelling reason to preserve existing vascular access (i.e., need for chronic dialysis; younger patient with anticipated long-term need for ICD therapy) o History of need for explantation of a transvenous ICD due to a complication, with ongoing need for ICD therapy • Have no indication for antibradycardia pacing • Do not have ventricular arrhythmias known or anticipated to respond to antitachycardia pacing
The use of a subcutaneous ICD is considered investigational for individuals who do not meet the criteria outlined above.
Indications for consideration for ICD placement for each cardiac ion channelopathy are as follows:
• Note: For congenital LQTS, patients may have 1 or more clinical or historical findings other than those outlined above that could, alone or in combination, put them at higher risk for sudden cardiac death. They can include patients with a family history of sudden cardiac death due to LQTS, infants with a diagnosis of LQTS with functional 2:1 atrioventricular block, patients with a diagnosis of LQTS in conjunction with a diagnosis of Jervell and Lange-Nielsen syndrome or Timothy syndrome, and patients with a diagnosis of LQTS with profound QT prolongation (greater than 550 ms). These factors should be evaluated on an individualized basis by a clinician with expertise in LQTS when considering the need for ICD placement.
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terminate these arrhythmias to reduce the risk of sudden death. A subcutaneous ICD (S-ICD), which lacks transvenous leads, is intended to reduce lead-related complications.
Related Policies
• Biventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure
Benefit Application
Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.
Some state or federal mandates (e.g., Federal Employee Program [FEP] ) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.
Regulatory Status Transvenous Implantable Cardioverter Defibrillators
A large number of ICDs have been approved by the FDA through the premarket approval (PMA) process (FDA product code: LWS). A 2014 review of the FDA approvals of cardiac implantable devices reported that, between 1979 and 2012, the FDA approved 19 ICDs (7 pulse generators, 3 leads, 9 combined systems) through new PMA applications. 1 Many originally approved ICDs have received multiple supplemental applications. A selective summary of some currently available ICDs is provided in Table 1 .
Subcutaneous ICDs
In 2012, the Subcutaneous Implantable Defibrillator (S-ICD ™ ) System was approved by the FDA through the PMA process for the treatment of life-threatening ventricular tachyarrhythmias in patients who do not have symptomatic bradycardia, incessant VT, or spontaneous, frequently recurring VT that is reliably terminated with antitachycardia pacing (see Table 1 ). In 2015, the Emblem ™ S-ICD (Boston Scientific), which is smaller and longer-lasting than the original S-ICD, was approved by the FDA through the PMA supplement process. Note: ICDs may be combined with other pacing devices, such as pacemakers for atrial fibrillation, or biventricular pacemakers designed to treat heart failure. This evidence review addresses ICDs alone when used solely to treat patients at risk for ventricular arrhythmias.
Rationale Background Ventricular Arrhythmia and Sudden Cardiac Death
The risk of ventricular arrhythmia and sudden cardiac death (SCD) may be significantly increased in various cardiac conditions such as ischemic cardiomyopathy, particularly when associated with reduced left ventricular ejection fraction and prior myocardial infarction; nonischemic dilated cardiomyopathy with reduced left ventricular ejection fraction; hypertrophic cardiomyopathy and additional risk factors; congenital heart disease, particularly with recurrent syncope; and cardiac ion channelopathies.
Treatment
Implantable cardioverter defibrillators (ICDs) monitor a patient's heart rate, recognize ventricular fibrillation or ventricular tachycardia (VT), and deliver an electric shock to terminate these arrhythmias to reduce the risk of SCD. Indications for ICD placement can be broadly subdivided into (1) secondary prevention, ie, use in patients who have experienced a potentially lifethreatening episode of VT (near SCD); and (2) primary prevention, ie, use in patients who are considered at high risk for SCD but who have not yet experienced life-threatening VT or ventricular fibrillation.
The standard ICD placement surgery involves placement of a generator in the subcutaneous tissue of the chest wall. Transvenous leads are attached to the generator and threaded intravenously into the endocardium. The leads sense and transmit information on cardiac rhythm to the generator, which analyzes the rhythm information and produces an electrical ventricular fibrillation shock when a malignant arrhythmia is recognized.
A subcutaneous ICD (S-ICD) has been developed. It does not use transvenous leads and thus avoids the need for venous access and complications associated with the insertion of venous leads. Rather, the S-ICD uses a subcutaneous electrode implanted adjacent to the left sternum. The electrodes sense the cardiac rhythm and deliver countershocks through the subcutaneous tissue of the chest wall.
Several automatic ICDs have been approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process. FDA-labeled indications generally include patients who have experienced life-threatening VT associated with cardiac arrest or VT associated with hemodynamic compromise and resistance to pharmacologic treatment. Also, devices typically have approval in the secondary prevention setting for patients with previous myocardial infarction and reduced injection fraction.
Literature Review
Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to functionincluding benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.
To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, two domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable 7.01. 44 Implantable Cardioverter Defibrillators Page 7 of 41 intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.
Transvenous Implantable Cardioverter Defibrillators Primary Prevention in Adults
Transvenous implantable cardioverter defibrillators (TV-ICDs) have been evaluated for primary prevention in a number of populations considered at high risk of sudden cardiac death (SCD), including those with ischemic cardiomyopathy, nonischemic dilated cardiomyopathy (NIDCM), and hypertrophic cardiomyopathy (HCM). There is a large body of evidence, including a number of RCTs and systematic reviews of these trials, addressing the role of ICDs for primary prevention and identifying specific populations who may benefit.
Ischemic Cardiomyopathy and NIDCM Randomized Controlled Trials
At least 13 RCTs of ICDs for primary prevention have been conducted. Five were in populations with ischemic cardiomyopathy with prior myocardial infarction (MI; usually ≥3 weeks post-MI):
• The characteristics and mortality results for these 3 groups of trails are shown in Table 2 .
Most trials for both ischemic and nonischemic cardiomyopathy have reported results consistent with a mortality benefit for ICD in patients with left ventricular systolic dysfunction or with heart failure and reduced ejection fraction, although not all trials were powered for the mortality outcome and some findings were not statistically significant. However, the DINAMIT, IRIS, and BEST-ICD trials did not support a mortality benefit for ICD in the early weeks following MI, and CABG Patch showed no benefit in patients having recently undergone coronary revascularization. Another notable exception is the 2016 DANISH trial, which enrolled primarily outpatients with nonischemic cardiomyopathy (NICM) in stable condition who were almost all receiving β-blocker or angiotensin-converting enzyme inhibitors, with the majority also receiving mineralocorticoid-receptor antagonists. Woods et al (2015) published an individual patient data network meta-analysis of primary prevention RCTs evaluating implantable cardiac devices, including studies of patients with heart failure and reduced ejection fraction and excluding studies of patients with recent MI or coronary revascularization. 15 The COMPANION, DEFINITE, MADIT, MADIT II, SCD HeFT, AMIOVIRT, and CAT trials were included, representing 6134 patients for the direct ICD comparisons and 12,638 patients overall. The overall estimated effect of ICD on mortality compared with medical therapy was 0.71 (95% CI, 0.63 to 0.80).
Systematic Reviews
Subsequent systematic reviews and meta-analyses of ICD trials in NICM incorporated the 2016 DANISH trial results. [16] [17] [18] [19] Two reviews published in 2017 included the CAT, AMIOVIRT, DEFINITE, SCD HeFT, COMPANION, and DANISH trials; other reviews included all but the COMPANION trial. All reviews have concluded that there was a statistically significant overall reduction in mortality for ICD vs medical therapy, ranging from 20% to 23%, even with the inclusion of the null DANISH results.
The risk for death varies by age, sex, and clinical characteristics such as LVEF and time since revascularization and comorbid conditions (e.g., diabetes, kidney disease). Meta-analyses have examined whether there is a beneficial effect on mortality of ICD in these subgroups. Earley et al (2014) conducted a review of evidence for the Agency for Healthcare Research and Quality on use of ICD across important clinical subgroups. 20 Reviewers included 10 studies that provided subgroup analyses. Subgroup data were available from at least 4 studies for sex, age (<65 years vs ≥65 years), and QRS interval (<120 ms vs ≥120 ms); they were combined to calculate a relative odds ratio (ROR) using random-effects meta-analyses. There was no statistically significant difference in the mortality benefit by sex (ROR=0.95; 95% CI, 0.75 to 1.27), age (ROR=0.93; 95% CI, 0.73 to 1.20), or QRS interval (ROR=1.13; 95% CI, 0.82 to 1.54). Other comparisons of subgroups were not meta-analyzed because too few studies compared them; however, no consistent differences between subgroups were found across studies for diabetes. The Woods individual patient data network meta-analysis (described previously) also examined ICD and medical therapy in various subgroups, and similarly concluded that ICD reduced mortality in patients with heart failure and reduced ejection for QRS interval less than 120 ms, 120 to 149 ms, and 150 ms or higher, age less than 60 and 60 and older, and for men. 15 However, the effect on mortality in women was not statistically significant (HR=0.93; 95% CI, 0.73 to 1.18). Fontenla et al (2016) reported on results from the Spanish UMBRELLA Registry, a multicenter, observational, prospective nationwide registry of 1514 patients implanted with Medtronic ICDs equipped with remote monitoring (NTC01561144) who were enrolled between 2012 and 2013. 21 Mean age was 64 years; 82% of the patients were men; and 65% received an ICD for primary prevention. Fifty-one percent of the patients had ischemic heart disease, 30% had NICM, 7% had HCM, 3% had Brugada syndrome (BrS), and 1.4% had long QT syndrome (LQTS). Mean follow-up was 26 months. The cumulative incidence of sustained ventricular arrhythmias was 15% (95% CI, 13% to 16%) at 1 year, 23% (95% CI, 21% to 25%) at 2 years, and 31% (95% CI, 28% to 34%) at 3 years. Thirteen percent of the episodes of sustained ventricular arrhythmias self-terminated and did not require shocks. One hundred seventy-five (12%) patients had 482 appropriate shocks, and 76 (5%) patients had 190 inappropriate shocks. Schinkel et al (2012) conducted a systematic review and meta-analysis of 27 observational studies (16 cohorts, 2190 patients) reporting outcomes after ICD therapy for HCM. 22 Most patients (83%) received an ICD for primary prevention of SCD. Mean age was 42, 38% of patients were women, and patients had a mean of 1.8 risk factors for SCD. With a mean follow-up of 3.7 years, 14% of patients had an appropriate ICD intervention with an annualized rate of 3.3%. Twenty percent of patients had an inappropriate ICD intervention, for an annualized rate of 4.8%. The annualized cardiac mortality rate was 0.6%, the noncardiac mortality rate was 0.4%, and heart transplantation rate was 0.5%.
Registry Studies
High-Risk HCM
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Implantable Cardioverter Defibrillators Page 12 of 41 Magnusson et al (2015) reported on outcomes for 321 patients with HCM treated with an ICD and enrolled in a Swedish registry. 23 Over a mean follow-up of 5.4 years, appropriate ICD discharges in response to ventricular tachycardia (VT) or ventricular fibrillation (VF) occurred in 77 (24%) patients, corresponding to an annual rate of appropriate discharges of 5.3%. At least 1 inappropriate shock occurred in 46 (14.3%) patients, corresponding to an annualized event rate of 3.0%. Ninety-two (28.7%) patients required at least 1 surgical intervention for an ICD-related complication, with a total of 150 ICD-related reinterventions. Most reinterventions (n=105 [70%]) were related to lead dysfunction.
Inherited Cardiac Ion Channelopathy
ICDs have been used for primary and secondary prevention in patients with a number of hereditary disorders (also called cardiac ion channelopathies) that predispose to ventricular arrhythmias and SCD, including LQTS, BrS, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT). Some of these conditions are extremely rare. Use of ICDs has been described in small cohorts of patients with LQTS, BrS, and CPVT.
Long QT Syndrome
Horner et al (2010) reported on outcomes for 51 patients with genetically confirmed LQTS treated with an ICD from 2000 to 2010 who were included in a single-center retrospective analysis of 459 patients with genetically confirmed LQTS. 24 Of patients treated with ICDs, 43 (84%) received the device as primary prevention. Twelve (24%) patients received appropriate VF or torsades de pointes−terminated ICD shocks. Factors associated with appropriate shocks included secondary prevention indications (p=0.008), QT corrected duration greater than 500 ms (p<0.001), non-LQT3 genotype (p=0.02), documented syncope (p=0.05), documented torsades de pointes (p=0.003), and a negative sudden family death history (p<0.001). Inappropriate shocks were delivered in 15 (29%) patients. Patients with the LQT3 genotype only received inappropriate shocks.
Brugada Syndrome
Hernandez-Ojeda et al (2017) reported on results from a single-center registry of 104 patients with BrS who were treated with ICDs. 25 Ten (9.6%) patients received an ICD for secondary prevention and in 94 (90.4%) patients received an ICD for primary prevention. During an average 9.3-year follow-up, 21 (20.2%) patients received a total of 81 appropriate shocks. In multivariate analysis, type 1 electrocardiogram with syncope and secondary prevention indication were significant predictors of appropriate therapy. Nine (8.7%) patients received 37 inappropriate shocks. Twenty-one (20.2%) patients had other ICD-related complications. Conte et al (2015) described outcomes for a cohort of 176 patients with spontaneous or druginduced Brugada type 1 electrocardiographic (ECG) findings who received an ICD at a single institution and were followed for at least 6 months. 26 Before ICD implantation, 14.2% of subjects had a history of aborted SCD due to sustained spontaneous ventricular arrhythmias, 59 .7% had at least 1 episode of syncope, and 25.1% were asymptomatic. Over a mean follow-up of 83.8 months, 30 (17%) patients had spontaneous sustained ventricular arrhythmias detected. Sustained ventricular arrhythmias were terminated by ICD shocks in 28 (15.9%) patients and antitachycardia pacing in 2 (1.1%) patients. However, 33 (18.7%) patients experienced inappropriate shocks. (2015) reported on results of a Portuguese registry that included 55 patients with BrS, 36 of whom were treated with ICDs for primary or secondary prevention. 27 Before ICD placement, 52.8% of subjects were asymptomatic, 30.6% had a history of syncope with suspected arrhythmic cause, and 16.7% had a history of aborted SCD. Over a mean follow-up of 74 months, 7 patients experienced appropriate shocks, corresponding to an incidence rate of 19.4% and an annual event rate of 2.8%. In multivariable analysis, predictors of appropriate shocks were a history of aborted SCD (HR=7.87; 95% CI, 1.27 to 49.6; p=0.027) and nonsustained VT during follow-up (HR=6.73; 95% CI, 1.27 to 35.7; p=0.025).
Dores et al
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Catecholaminergic Polymorphic Ventricular Tachycardia Roses-Noguer et al (2014) reported on results of a small retrospective study of 13 patients with CPVT who received an ICD. 28 The indication for ICD therapy was syncope despite maximal β-blocker therapy in 6 (46%) patients and aborted SCD in 7 (54%) patients. Over a median followup of 4.0 years, 10 (77%) patients received a median of 4 shocks. For 96 shocks, 87 ECGs were available for review; of those, 63 (72%) were appropriate and 24 (28%) inappropriate. Among appropriate shocks, 20 (32%) restored sinus rhythm.
Section Summary: Transvenous Implantable Cardioverter Defibrillators for Primary Prevention in Adults
Ischemic Cardiomyopathy and NIDCM A large body of RCTs has addressed the effectiveness of TV-ICD implantation for primary prevention in patients at high risk of SCD due to ischemic cardiomyopathy and NICM. Evidence from several RCTs has demonstrated improvements in outcomes with ICD treatment for patients with symptomatic heart failure due to ischemic or NICM with an LVEF of 35% or less. The notable exceptions are that data from several RCTs, including the BEST-ICD, DINAMIT and IRIS trials and subgroup analyses from earlier RCTs, have shown that outcomes with ICD therapy do not appear to improve for patients treated with an ICD within 40 days of recent MI and the CABG Patch trial did not find a benefit for patients undergoing coronary revascularization.
Hypertrophic Cardiomyopathy
Less evidence is available for the use of ICDs for primary prevention in patients with HCM. In a meta-analysis of cohort studies, the annual rates of appropriate ICD discharge were 3.3%, and the mortality rate was 1%. Given the long-term high risk of SCD in patients with HCM, with the assumption that appropriate shocks are life-saving, these rates are considered adequate evidence for the use of SCDs in patients with HCM.
Inherited Cardiac Ion Channelopathy
The evidence related to the use of ICDs in patients with inherited cardiac ion channelopathy includes primarily single-center cohort studies or registries of patients with LQTS, BrS, and CPVT that have reported on appropriate shock rates. Patient populations typically include a mix of those requiring ICD placement for primary or secondary prevention. The limited available data for ICDs for LQTS and CPVT have indicated high rates of appropriate shocks. For BrS, more data are available and have suggested that rates of appropriate shocks are similarly high. Studies comparing outcomes between patients treated and untreated with ICDs are not available. However, given the relatively small patient populations and the high risk of cardiac arrhythmias, clinical trials are unlikely. Given the long-term high risk of SCD in patients with inherited cardiac ion channelopathy, with the assumption that appropriate shocks are life-saving, these rates are considered adequate evidence for the use of SCDs in patients with inherited cardiac ion channelopathy.
Secondary Prevention in Adults
At least 5 trials comparing ICD plus medical therapy with medical therapy alone have been conducted in the secondary prevention setting: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial 29 (N=1016), Cardiac Arrest Survival in Hamburg (CASH) trial 30 (N=288), Canadian Implantable Defibrillator Study (CIDS) 31 (N=659), Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT) 32 trial (N=66; pilot, n=20; main study, n=46), and Wever et al (1995) 33 (N=60). The trials are shown in Table 3 . Mean length of follow-up varied from 18 to 57 months across trials. Lee et al (2003) combined the AVID, CASH, CIDS, and Wever et al (1995) trials in a meta-analysis of secondary prevention trials. 34 The mortality analysis included 2023 participants and 518 events. In combined estimates, the ICD group had a significant reduction in both mortality (HR=0.75; 95% CI, 0.64 to 0.87) and SCD (HR=0.50; 95% CI, 0.34 to 0.62) compared with the group receiving medical therapy alone. To support National Institute for Health and Care Excellence guidance on the use of ICDs, AVID, CASH, CIDS, and the pilot DEBUT participants were combined in a meta-analysis. 35 The results were similar, indicating a reduction in mortality for ICDs compared with medical therapy alone (relative risk [RR], 0.75; 95%
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Implantable Cardioverter Defibrillators Page 14 of 41 CI, 0.61 to 0.93). Two other meta-analyses that included AVID, CIDS, and CASH reached similar conclusions. 36, 37 An analysis by Chan and Hayward (2005) using the National Veterans Administration database previously confirmed that this mortality benefit is generalizable to the clinical setting. 38 A cohort of 6996 patients in the National Veterans Administration database, from 1995 to 1999, who had new-onset ventricular arrhythmia and preexisting ischemic heart disease and congestive heart failure were included. Of those, 1442 patients had received an ICD. Mortality was determined through the National Death Index at 3 years from the hospital discharge date. The cohort was stratified by quintiles of a multivariable propensity score created using many demographic and clinical confounders. The propensity score-adjusted mortality reduction for ICD compared with no ICD was an RR of 0.72 (95% CI, 0.69 to 0.79) for all-cause mortality and an RR of 0.70 (95% CI, 0.63 to 0.78) for cardiovascular mortality.
Section Summary: Secondary Prevention in Adults Systematic reviews of RCTs in patients who have experienced symptomatic life-threatening sustained VT or VF or have been successfully resuscitated from sudden cardiac arrest have shown a 25% reduction in mortality for ICD compared with medical therapy. Analysis of data from a large administrative database has confirmed that this mortality benefit is generalizable to the clinical setting.
TV-ICDS in Pediatric Populations
There is limited direct evidence on the efficacy of ICDs in the pediatric population. Most published studies have retrospectively analyzed small case series. Some representative series are reviewed next.
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The largest published series, by Berul et al (2008) , combined pediatric patients and patients with congenital heart disease from 4 clinical centers. 39 Median age was 16 years, although some adults included were as old as 54 years. A total of 443 patients were included. The most common diagnoses were tetralogy of Fallot and HCM. ICD placement was performed for primary prevention in 52% of patients and secondary prevention in 48%. Over a 2-year follow-up, appropriate shocks occurred in 26% of patients and inappropriate shocks occurred in 21%. Silka et al (1993) compiled a database of 125 pediatric patients treated with an ICD through a query of the manufacturers of commercially available devices. 40 Indications for ICD placement were survivors of cardiac arrest (95 [76%] patients), drug-refractory VT (13 [10%] patients), and syncope with heart disease and inducible VT (13 [10%] patients). During a mean follow-up of 31 months, 73 (59%) patients received at least 1 appropriate shock and 25 (20%) received at least 1 inappropriate shock. Actuarial rates of SCD-free survival were 97% at 1 year, 95% at 2 years, and 90% at 5 years.
Alexander et al (2004) reported on 90 ICD procedures in 76 young patients (mean age, 16 years; range, 1-30 years). 41 Indications for placement were 27 (36%) patients with cardiac arrest or sustained VT, 40 (53%) with syncope, 17 (22%) with palpitations, 40 (53%) with spontaneous ventricular arrhythmias, and 36 (47%) with inducible VT. Numerous patients had more than 1 indication for ICD in this study. Over a median follow-up of 2 years, 28% of patients received an appropriate shock and 25% received an inappropriate shock. Lewandowski et al (2010) reported on long-term follow-up for 63 patients, between the ages 6 and 21 years, who were treated with an ICD device. 42 At 10-year follow-up, 13 (21%) patients had surgical infections. Fourteen (22%) patients experienced at least 1 appropriate shock and 17 (27%) had at least 1 inappropriate shock. Serious psychological sequelae developed in 27 (43%) patients.
Section Summary: TV-ICDs in Pediatric Populations
The available evidence for the use of ICDs in pediatric patients is limited and consists primarily of small case series that include mixed populations with mixed indications for device placement. Overall, these studies have reported both relatively high rates of appropriate and inappropriate shocks. Pediatric patients may be eligible for ICD placement if they have inherited cardiac ion channelopathy (see Inherited Cardiac Ion Channelopathy section).
Adverse Events Associated with TV-ICDS Systematic Reviews: Mixed Adverse Events
Persson et al (2014) conducted a systematic review of adverse events following ICD placement. 43 They included data from 35 cohort studies, reported in 53 articles. In-hospital serious adverse event rates ranged from 1.2% to 1.4%, most frequently pneumothorax (0.4%-0.5%) and cardiac arrest (0.3%). Posthospitalization complication rates varied: device-related complications occurred in 0.1% to 6.4%; lead-related complications in 0.1% to 3.9% of patients; infection in 0.2% to 3.7%; thrombosis in 0.2% to 2.9%; and inappropriate shock in 3% to 21%.
In another systematic review of adverse events following ICD placement, Ezzat et al (2015) compared event rates reported in clinical trials of ICDs with those reported in the U.S. National Cardiovascular Data Registry. 44 Reviewers included 18 RCTs (total N=6796 patients). In the pooled analysis, the overall adverse event rate was 9.1% (95% CI, 6.4% to 12.6%). Rates of access-related complications, lead-related complications, generator-related complications, and infection were 2.1% (91% CI, 1.3% to 3.3%), 5.8% (95% CI, 3.3% to 9.8%), 2.7% (95% CI, 1.3% to 5.7%), and 1.5% (95% CI, 0.8% to 2.6%), respectively. Complication rates in the RCTs were higher than those in the U.S. registry, which reports only in-hospital complications (9.1% in the RCTs vs 3.08% in the U.S. registry, p<0.01). The overall complication rate was similar to that reported by Kirkfelt et al (2014) , in a population-based cohort study including all Danish patients who underwent a cardiac implantable electronic device procedure from 2010 to 2011 (562 [9.5%] 5918 patients with at least 1 complication). 45 Van Rees et al (2011) reported on results of a systematic review of RCTs assessing implant-related complications of ICDs and cardiac resynchronization therapy (CRT) devices. 46 Reviewers 7.01. 44 Implantable Cardioverter Defibrillators Page 16 of 41 included 18 trials and 3 subgroup analyses. Twelve trials assessed ICDs, 4 of which used both thoracotomy and nonthoracotomy ICDs (n=951) and 8 of which used nonthoracotomy ICDs (n=3828). For nonthoractomy ICD placement, the rates for in-hospital and 30-day mortality were 0.2% and 0.6%, respectively, and pneumothorax was reported in 0.9% of cases. For thoracotomy ICD placement, the average in-hospital mortality rate was 2.7%. For nonthoracotomy ICD placement, the overall lead dislodgement rate was 1.8%.
Olde Nordkamp et al (2016) reported on a systematic review and meta-analysis of studies reporting on ICD complications in individuals with inherited arrhythmia syndromes. 47 
Systematic Review: Specific Complications Lead Failure
The failure of leads in specific ICD devices led the U.S. Food and Drug Administration to require St. Jude Medical to conduct 3-year postmarket surveillance studies to address concerns related to premature insulation failure and important questions related to follow-up of affected patients. 48 An evaluation by Hauser et al (2010) found that 57 deaths and 48 serious cardiovascular injuries associated with device-assisted ICD or pacemaker lead extraction were reported to the Food and Drug Administration's Manufacturers and User Defined Experience database. 49 Providencia et al (2015) reported on a meta-analysis of 17 observational studies evaluating the performance of 49,871 leads (5538 Durata, 10,605 Endotak Reliance, 16119 Sprint Quattro, 11,709 Sprint Fidelis, 5900 Riata). 50 Overall, the incidence of lead failure was 0.93 per 100 lead-years (95% CI, 0.88 to 0.98). In an analysis of studies restricted to head-to-head comparisons of leads, there were no significant differences in the lead failure rates among nonrecalled leads (Endotak Reliance, Durata, Sprint Quattro). In a large prospective multicenter study, Poole et al (2010) reported on complications rates associated with generator replacements and/or upgrade procedures of pacemaker or ICD devices, which included 1031 patients without a planned transvenous lead replacement (cohort 1) and 713 with a planned transvenous lead replacement (cohort 2). 54 A total of 9.8% and 21.9% of cohort 1 and 19.2% and 25.7% of cohort 2 had a single chamber ICD and a dual chamber ICD, respectively, at baseline. Overall periprocedural complication rates for those with a planned transvenous lead replacement were a cardiac perforation in 0.7%, pneumothorax or hemothorax in 0.8%, cardiac arrest in 0.3%, and, most commonly, need to reoperate because of 7.01. 44 Implantable
, complication rates were higher for ICDs and CRT devices than pacemakers. Ricci et al (2012) evaluated the incidence of lead failure in a cohort of 414 patients given an ICD with Sprint Fidelis leads. 55 Patients were followed for a median of 35 months. Lead failures occurred in 9.7% (40/414) of patients, for an annual rate of 3.2% per patient-year. Most lead failures (87.5%) were due to lead fracture. Median time until recognition of lead failure, or until an adverse event, was 2.2 days. A total of 22 (5.3%) patients received an inappropriate shock due to lead failure.
Cheng et al (2010) examined the rate of lead dislodgements in patients enrolled in a national cardiovascular registry. 56 Of 226,764 patients treated with an ICD between 2006 and 2008, lead dislodgement occurred in 2628 (1.2%). Factors associated with lead dislodgement were New York Heart Association class IV heart failure, AF or atrial flutter, a combined ICD and CRT device, and having the procedure performed by a nonelectrophysiologist. Lead dislodgement was associated with an increased risk for other cardiac adverse events and death.
In another single-center study, Faulknier et al (2010) reported on the time-dependent hazard of failure of Sprint Fidelis leads. 57 Over an average follow-up of 2.3 years, 38 (8.9%) of 426 leads failed. There was a 3-year lead survival rate of 90.8% (95% CI, 87.4% to 94.3%), with a hazard of fracture increasing exponentially over time by a power of 2.13 (95% CI, 1.98 to 2.27; p<0.001).
Infection Rates
Several publications have reported on infection rates in patients receiving an ICD. Smit et al (2010) published a retrospective, descriptive analysis of the types and distribution of infections associated with ICDs over a 10-year period in Denmark. 58 Of 91 total infections identified, 39 (42.8%) were localized pocket infections, 26 (28.6%) were endocarditis, 17 (18.7%) were ICDassociated bacteremic infections, and 9 (9.9%) were acute postsurgical infections. Nery et al (2010) reported on the rate of ICD-associated infections among consecutive patients treated with an ICD at a tertiary referral center. 59 Twenty-four of 2417 patients had infections, for a rate of 1.0%. Twenty-two (91.7%) of the 24 patients with infections required device replacement. Factors associated with infection were device replacement (vs de novo implantation) and use of a complex device (e.g., combined ICD plus CRT or dual-/triple-chamber devices). Sohail et al (2011) performed a case-control study evaluating the risk factors for an ICD-related infection in 68 patients and 136 matched controls. 60 On multivariate analysis, the presence of epicardial leads (odds ratio [OR], 9.7; p=0.03) and postoperative complications at the insertion site (OR=27.2, p<0.001) were significant risk factors for early infection. For late-onset infections, hospitalization for more than 3 days (OR=33.1, p<0.001 for 2 days vs 1 day) and chronic obstructive pulmonary disease (OR=9.8, p=0.02) were significant risk factors.
Chua et al (2000) described the diagnosis and management of infections in a retrospective case series that included 123 patients, 36 of whom were treated for ICD infections. 61 Most (n=117 [95%]) patients required removal of the device and all lead material. Of those who had all hardware removed, 1 patient experienced a relapse, while 3 of the 6 patients who did not undergo hardware removal experienced a relapse.
Borleffs et al (2010) also reported on complications after ICD replacement for pocket-related complications, including infection or hematoma, in a single-center study. 62 Of 3161 ICDs included, 145 surgical reinterventions were required for 122 ICDs in 114 patients. Ninety-five (66%) reinterventions were due to infection, and the remaining 50 (34%) were due to other causes. Compared with first-implanted ICDs, the occurrence of surgical reintervention in replacements was 2.5 (95% CI, 1.6 to 3.7) times higher for infection and 1.7 (95% CI, 0.9 to 3.0) times higher for non-infection-related causes.
Inappropriate Shocks
Inappropriate shocks may occur with ICDs due to faulty sensing or sensing of atrial arrhythmias with rapid ventricular conduction; these shocks may lead to reduced QOL and risk of ventricular 7.01. 44 Implantable Cardioverter Defibrillators Page 18 of 41 arrhythmias. In the MADIT II trial (described above), 1 or more inappropriate shocks occurred in 11.5% of ICD subjects and were associated with a greater likelihood of mortality (HR=2.29; 95% CI, 1.11 to 4.71; p=0.02). 63 Tan et al (2014) conducted a systematic review to identify outcomes and adverse events associated with ICDs with built-in therapy-reduction programming. 64 Six randomized trials and 2 nonrandomized cohort studies (total N=7687 patients) were included (3598 with conventional ICDs, 4089 therapy-reduction programming). A total of 267 (4.9%) patients received inappropriate ICD shocks, 99 (3.4%) in the therapy-reduction group and 168 (6.9%) in the conventional programming group (RR=0.50; 95% CI, 0.37 to 0.61; p<0.001). Therapy-reduction programming was associated with a significantly lower risk of death than conventional programming (RR=0.30; 95% CI, 0.16 to 0.41; p<0.001.)
Sterns et al (2016) reported on results of an RCT comparing a strategy using a prolonged VF detection time to reduce inappropriate shocks with a standard strategy among secondary prevention patients. 65 This trial reported on a prespecified subgroup analysis of the PainFree SST trial, which compared standard with prolonged detection in patients receiving an ICD for secondary prevention. Patients treated for secondary prevention indications were randomized to a prolonged VF detection period (n=352) or a standard detection period (n=353). At 1 year, arrhythmic syncope-free rates were 96.9% in the intervention group, and 97.7% in the control group (rate difference, -1.1%; 90% lower confidence limit, -3.5%; above the prespecified noninferiority margin of -5%; p=0.003 for noninferiority).
Auricchio et al (2015) assessed data from the PainFree SST trial, specifically newer ICD programming strategies for reducing inappropriate shocks. 66 A total of 2790 patients with an indication for ICD placement were given a device programmed with a SmartShock Technology designed to differentiate between ventricular arrhythmias and other rhythms. The inappropriate shock incidence for dual-/triple-chamber ICDs was 1.5% at 1 year (95% CI, 1.0% to 2.1%), 2.8% at 2 years (95% CI, 2.1% to 3.8%), and 3.9% at 3 years (95% CI, 2.8% to 5.4%).
Other Complications
Lee et al (2010) evaluated rates of early complications among patients enrolled in a prospective, multicenter population-based registry of all newly implanted ICDs in Ontario, from 2007 through 2009. 67 Of 3340 patients receiving an ICD, major complications (lead dislodgement requiring intervention, myocardial perforation, tamponade, pneumothorax, infection, skin erosion, hematoma requiring intervention) within 45 days of implantation occurred in 4.1% of new implants. Major complications were more common in women, in patients who received a combined ICD-CRT device, and in patients with a left ventricular end-systolic size of larger than 45 mm. Direct implant-related complications were associated with a major increase in early death (HR=24.9; p<0.01).
Furniss et al (2015) prospectively evaluated changes in high-sensitivity troponin T levels and ECG results that occur during ICD placement alone, ICD placement with testing, and ICD testing alone. 68 The 13 subjects undergoing ICD placement alone had a median increase in highsensitivity troponin T level of 95% (p=0.005) while the 13 undergoing implantation and testing had a median increase of 161% (p=0.005). Those undergoing testing alone demonstrated no significant change in high-sensitivity troponin T levels.
Subcutaneous Implantable Cardioverter Defibrillators
The subcutaneous ICD (S-ICD) is intended for patients who have standard indications for an ICD, but who do not require pacing for bradycardia or antitachycardia overdrive pacing for VT. The S-ICD has been proposed to benefit patients with limited vascular access (including patients undergoing renal dialysis or children) or those who have had complications requiring TV-ICDs explantation. No RCTs were identified comparing the performance of an S-ICD with that of TVICDs. The first multicenter, randomized trial (PRAETORIAN; NCT01296022) to directly compare SICDs with TV-ICDs is underway.
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S-ICD Efficacy
Several observational studies have compared S-ICD to TV-ICD.
Observational Studies
The observational studies are briefly described in Table 4 . All studies were performed in the United States and/or Europe.
Noncomparative Studies
The EFFORTLESS S-ICD Registry is a multicenter European registry reporting outcomes for patients treated with S-ICD. Several publications from EFFORTLESS, the pivotal trial submitted to the Food and Drug Administration for the investigational device exemption, and other noncomparative studies are described in Table 5 . 
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Inappropriate Shocks
Although Kobe et al (2017) reported no differences between inappropriate shock rates in patients treated TV-ICD or S-ICD, noncomparative studies have reported relatively high rates of inappropriate shocks with S-ICD. 71 Inappropriate shocks from S-ICDs often result from T-wave oversensing. Because the sensing algorithm and the discrimination algorithm for arrhythmia detection are fixed in the S-ICD, management to reduce inappropriate shocks for an S-ICD differs from that for a TV-ICD. Kooiman et al (2014) reported on inappropriate shock rates among 69 patients treated at a single center with an S-ICD between 2009 and 2012 who were not enrolled in 1 of 2 other concurrent trials. 86 Over a total follow-up of 1316 months (median per patient, 21 months), the annual incidence of inappropriate shocks was 10.8%. In 8 patients, inappropriate shocks were related to T-wave oversensing. After patients underwent adjustment of the sensing vector, no further inappropriate shocks occurred in 87.5% of patients with T-wave oversensing.
Section Summary: Subcutaneous Implantable Cardioverter Defibrillators
Contraindications to TV-ICD Nonrandomized studies have suggested that S-ICDs are as effective as TV-ICDs at terminating laboratory-induced ventricular arrhythmias. Data from 2 large patient registries have suggested that S-ICDs are effective at terminating ventricular arrhythmias when they occur. Given the need for cardioverter defibrillation for SCD risk in this population, with the assumption that appropriate shocks are life-saving, these rates suggest S-ICDs, in patients with contraindication to TV-ICD, are likely improvements over medical management alone.
No Contraindications to TV-ICD
No RCTs directly comparing TV-ICDs with S-ICDs were identified, and therefore evidence is not sufficient to show that outcomes for S-ICDs are noninferior to those for TV-ICD for patients who could otherwise receive TV-ICD.
Summary of Evidence Transvenous ICDs
For individuals who have a high risk of SCD due to ischemic or to nonischemic cardiomyopathy in adulthood who receive TV-ICD placement for primary prevention, the evidence includes multiple well-designed and well-conducted RCTs as well as systematic reviews of these trials. Relevant outcomes are overall survival, morbid events, quality of life, and treatment-related mortality and morbidity. Multiple, well-done RCTs have shown a benefit in overall mortality for patients with ischemic cardiomyopathy and reduced ejection fraction. RCTs assessing early ICD use following recent myocardial infarction did not support a benefit for immediate vs delayed implantation for at least 40 days. For nonischemic cardiomyopathy, there is less clinical trial data, but pooled estimates of available evidence from RCTs enrolling patients with nonischemic cardiomyopathy and from subgroup analyses of RCTs with mixed populations have supported a survival benefit for this group. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.
For individuals who have a high risk of SCD due to HCM in adulthood who receive TV-ICD placement for primary prevention, the evidence includes several large registry studies. Relevant outcomes are overall survival, morbid events, quality of life, and treatment-related mortality and morbidity. In these studies, the annual rate of appropriate ICD discharge ranged from 3.6% to 5.3%. Given the long-term high risk of SCD in patients with HCM, with the assumption that appropriate shocks are life-saving, these rates are considered adequate evidence to support the use of ICDs in patients with HCM. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.
For individuals who have a high risk of SCD due to an inherited cardiac ion channelopathy who receive TV-ICD placement for primary prevention, the evidence includes small cohort studies of patients with these conditions treated with ICDs. Relevant outcomes are overall survival, morbid events, quality of life, and treatment-related mortality and morbidity. The limited evidence for 7.01. 44 Implantable Cardioverter Defibrillators Page 23 of 41 patients with long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, and Brugada syndrome has reported high rates of appropriate shocks. No studies were identified on the use of ICDs for patients with short QT syndrome. Studies comparing outcomes between patients treated and untreated with ICDs are not available. However, given the relatively small patient populations with these channelopathies and the high risk of cardiac arrhythmias, clinical trials are unlikely. Given the long-term high risk of SCD in patients with inherited cardiac ion channelopathy, with the assumption that appropriate shocks are life-saving, these rates are considered adequate evidence to support the use of TV-ICDs in patients with inherited cardiac ion channelopathy. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.
For individuals who have had symptomatic life-threatening sustained VT or VF or who have been resuscitated from sudden cardiac arrest (secondary prevention) who receive TV-ICD placement, the evidence includes multiple well-designed and well-conducted RCTs as well as systematic reviews of these trials. Relevant outcomes are overall survival, morbid events, quality of life, and treatment-related mortality and morbidity. Systematic reviews of RCTs have demonstrated a 25% reduction in mortality for ICD compared with medical therapy. Analysis of data from a large administrative database has confirmed that this mortality benefit is generalizable to the clinical setting. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.
Subcutaneous ICDs
For individuals who need an ICD and have a contraindication to a TV-ICD but no indications for antibradycardia pacing and no antitachycardia pacing−responsive arrhythmias who receive S-ICD placement, the evidence includes nonrandomized studies and case series. Relevant outcomes are overall survival, morbid events, quality of life, and treatment-related mortality and morbidity. Nonrandomized controlled studies have reported success rates in terminating laboratory-induced VF that are similar to TV-ICD. Case series have reported high rates of detection and successful conversion of VF, and inappropriate shock rates in the range reported for TV-ICD. Given the need for ICD placement in this population at risk for SCD, with the assumption that appropriate shocks are life-saving, these rates are considered adequate evidence to support the use of S-ICDs in patients with contraindication to TV-ICD. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.
For individuals who have need for an ICD and have no contraindication to TV-ICD but no indications for antibradycardia pacing and no antitachycardia pacing−responsive arrhythmias who receive S-ICD placement, the evidence includes nonrandomized studies and case series. Relevant outcomes are overall survival, morbid events, quality of life, and treatment-related mortality and morbidity. Nonrandomized controlled studies have reported success rates in terminating laboratory-induced VF that are similar to TV-ICD. However, there is scant evidence on comparative clinical outcomes of both types of ICD over longer periods. Case series have reported high rates of detection and successful conversion of ventricular tachycardia, and inappropriate shock rates in the range reported for TV-ICD. This evidence does not support conclusions on whether there are small differences in efficacy between the 2 types of devices, which may be clinically important due to the nature to the disorder being treated. Also, adverse event rates are uncertain, with variable rates reported. At least 1 RCT is currently underway comparing S-ICD with TV-ICD. The evidence is insufficient to determine the effects of the technology on health outcomes.
Supplemental Information Clinical Input from Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.
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Input
In response to requests from Blue Cross Blue Shield Association, input was received from 1 physician specialty society (4 responses) and 5 academic medical centers, for a total of 9 responses in 2015. Input focused on the use of implantable cardioverter defibrillators (ICDs) as primary prevention for cardiac ion channelopathies and use of the subcutaneous implantable cardioverter defibrillator. Reviewers generally indicated that an ICD should be considered medically necessary for primary prevention of ventricular arrhythmias in adults and children with a diagnosis of long QT syndrome, Brugada syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia. Reviewers generally indicated that the subcutaneous implantable cardioverter defibrillator should be considered medically necessary particularly for patients with indications for an ICD but who have difficult vascular access or have had transvenous ICD lead explantation due to complications.
In response to requests from Blue Cross Blue Shield Association, input was received from 6 academic medical centers in 2011. For most policy indications, including pediatric, there was general agreement from those providing input. On the question of timing of ICD placement, input was mixed, with some commenting about the potential role of early implantation in select patients. Reviewers indicated that a waiting period of 9 months for patients with nonischemic cardiomyopathy was not supported by the available evidence or consistent with the prevailing practice patterns in academic medical centers. Input emphasized the difficulty of prescribing strict timeframes given the uncertainty of establishing the onset of cardiomyopathy and the inability to risk-stratify patients based on time since onset of cardiomyopathy.
Practice Guidelines and Position Statements American Heart Association et al
Heart Failure
The American Heart Association (AHA,) American College of Cardiology (ACC), and Heart Rhythm Society (HRS) (2017) published joint guidelines on the management of heart failure, which updated their 2012 guidelines. 87, 88 These guidelines made the following recommendations on the use of implantable cardioverter defibrillator (ICD) devices (see Tables 6-11 ). The recommendations for the use of an ICD apply only if meaningful survival is expected to be greater than 1 year. The 2013 update made the following recommendations on ICD therapy for children (see Table  12 ). 87 Table 12 . Guidelines on ICD Therapy for Children Recommendation COR LOE ICD implantation is indicated in the survivor of cardiac arrest after evaluation to define the cause of the event and to exclude any reversible causes.
Implantable Cardioverter Defibrillators
I B ICD implantation is indicated for patients with symptomatic sustained VT in association with congenital heart disease who have undergone hemodynamic and electrophysiological evaluation. Catheter ablation or surgical repair may offer possible alternatives in carefully selected patients.
I C ICD implantation is reasonable for patients with congenital heart disease with recurrent syncope of undetermined origin in the presence of either ventricular dysfunction or inducible ventricular arrhythmias at electrophysiological study.
IIa B
ICD implantation may be considered for patients with recurrent syncope associated with complex congenital heart disease and advanced systemic ventricular dysfunction when thorough invasive and noninvasive investigations have failed to define a cause.
IIb C
All class III recommendations found in Section 3, "Indications for Implantable CardioverterDefibrillator Therapy," apply to pediatric patients and patients with congenital heart disease, and ICD implantation is not indicated in these patient populations. 
ICD Therapy in Patients Not Well Represented in Clinical Trials
The HRS, ACC, and AHA (2014) published an expert consensus statement on the use of ICD therapy for patients not included or poorly represented in ICD clinical trials. 89 The statement presented a number of consensus-based guidelines on the use of ICDs in select patient populations.
American Heart Association AHA (2010) issued a scientific statement, endorsed by HRS, on cardiovascular implantable electronic device infections and their management. 90 This statement made the following recommendations on the removal of device-related infections (see Table 13 ). (2015) and endorsed by the Association for European Paediatric and Congenital Cardiology, issued guidelines on the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. 91 These guidelines make the following statements on use of device-based therapy for ventricular arrhythmia and prevention of sudden cardiac death (see Table 14 ). Heart Rhythm Society et al HRS, the European Heart Rhythm Association, and the Asia-Pacific Heart Rhythm Society (2013) issued a consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes, which included recommendations on ICD use in patients with long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome (see Table 15 ). 92 
Pediatric and Congenital Electrophysiology Society and Heart Rhythm Society
The Pediatric and Congenital Electrophysiology Society and HRS (2014) issued an expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease. The statement made the following recommendations on the use of ICD therapy in adults with congenital heart disease (see Table 16 ). 93 • Any disease, other than cardiac disease (e.g., cancer, uremia, liver failure), associated with a likelihood of survival less than 1 year;" Also, the Centers for Medicare & Medicaid Services specified that the beneficiary receiving an ICD for primary prevention must be enrolled in an approved clinical trial or a qualifying data collection system.
Ongoing and Unpublished Clinical Trials
Ongoing trials that may influence this review are listed in Table 17 . 
Policy History
This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy. 
Definitions of Decision Determinations
Medically Necessary: A treatment, procedure, or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition.
Investigational/Experimental: A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.
Split Evaluation: Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.
Prior Authorization Requirements (as applicable to your plan)
Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions. Questions regarding the applicability of this policy should be directed to the Prior Authorization Department. Please call (800) 541-6652 or visit the provider portal at www.blueshieldca.com/provider. 
